Evidence map›Paper›PMID 38390699›Full record

ArticleThoracic cancer2024

An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.

Paul F Hanona, Daniel Ezekwudo, Joseph Fullmer, Timothy Allen, Ishmael Jaiyesimi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. ThoracicJournal of thoracic disease · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul F HanonaDepartment of Hematology and Oncology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.ORCID 0000-0002-5762-1460
Daniel EzekwudoDepartment of Hematology and Oncology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.ORCID 0000-0002-3448-2541
Joseph FullmerDepartment of Hematology and Oncology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.ORCID 0000-0001-7037-3599
Timothy AllenDepartment of Hematology and Oncology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.
Ishmael JaiyesimiDepartment of Hematology and Oncology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.ORCID 0000-0002-6352-9054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4-deficient undifferentiated thoracic tumors are a rare phenomenon. A 40-year-old male was newly diagnosed with SMARCA4-deficient undifferentiated non-small cell lung cancer. He had a history of heavy smoking and job-related exposure to metal dust and melted nickel. CT imaging showed numerous right-sided pleural masses and soft tissue plaques, but no metastases. CT-guided biopsy of a pleural mass confirmed the diagnosis. He was prescribed six cycles of carboplatin paclitaxel, and follow-up imaging showed largely stable disease. Treatment was changed to nivolumab due to shortness of breath, and he received one cycle of nivolumab without considerable side effects. Unfortunately, during the second cycle of his nivolumab, the patient presented with new weakness. Imaging showed spinal cord metastasis and he underwent a laminectomy; he was subsequently followed up as an outpatient. The objective of this publication was to explore SMARCA4-deficient undifferentiated thoracic tumors, other related SMARCA4-deficient tumors, and their overall pattern of presentation. The genetic aberrations of this case are compared to recent publications that also discuss genetic aberrations commonly occurring with this disease process, with an ultimate goal of hastening detection and adding to the library of treatment results.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSarcomaThoracic NeoplasmsAdultBiomarkers, TumorDNA HelicasesHumansMaleNivolumabNuclear ProteinsTranscription FactorsBiomarkers, TumorDNA HelicasesNivolumabNuclear ProteinsSMARCA4 protein, humanTranscription Factorslung cancerSMARCA4SMARCA4‐deficient undifferentiated thoracic tumorsundifferentiated thoracic tumors

Identifiers

PMID38390699
PMCPMC10995709
OpenAlexW4392136297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.